Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock at an average price of $6.7202, according to a Form 4 filing.

Summary

• Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock on October 29, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at prices ranging from $6.67 to $6.83, with a weighted average sale price of $6.7202.
• Following the transaction, Borgeson directly owns 7,077,560 shares of Recursion Pharmaceuticals.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate sale price upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares over a period of time without being accused of trading on inside information. It is important to consider the size of the sale relative to the insider's holdings.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates